These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. HLA class II transgenic mice mimic human inflammatory diseases. Mangalam AK; Rajagopalan G; Taneja V; David CS Adv Immunol; 2008; 97():65-147. PubMed ID: 18501769 [TBL] [Abstract][Full Text] [Related]
11. [D-penicillamine-induced pemphigus, polymyositis and myasthenia]. Jan V; Callens A; Machet L; Machet MC; Lorette G; Vaillant L Ann Dermatol Venereol; 1999 Feb; 126(2):153-6. PubMed ID: 10352832 [TBL] [Abstract][Full Text] [Related]
12. A new mouse model of autoimmune ocular myasthenia gravis. Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462 [TBL] [Abstract][Full Text] [Related]
13. The effects of T cell subpopulations and recombinant interleukin (IL)-2 on peripheral B cell function in patients with myasthenia gravis. Zhang J; Zhou WB; Wang HL; Guo SS Hum Antibodies; 1997; 8(2):90-4. PubMed ID: 9289393 [TBL] [Abstract][Full Text] [Related]
14. TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains. Wu B; Shenoy M; Goluszko E; Kaul R; Christadoss P J Immunol; 1995 Apr; 154(7):3603-10. PubMed ID: 7897239 [TBL] [Abstract][Full Text] [Related]
15. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis. Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243 [TBL] [Abstract][Full Text] [Related]